Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Nippon India Nifty Pharma ETF Share Price
Day's Range
Day's Range
Low
₹24.24
High
₹25.36
Price Summary
| Previous Close | ₹24.75 |
|---|---|
| Day's Range | ₹24.24 - ₹25.36 |
| Open | ₹25.36 |
| 52 Week Range | N/A - N/A |
| Volume | 2,02,23,329 |
| Market Cap |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 5,005.27 |
|---|---|
| Market Cap (₹ in Mn) | |
| Dividend Yield(%) | |
| Price/Earning (TTM) | |
| TTM EPS (₹) | |
| P/E Ratio | |
| Book Value(₹) | |
| PAT Margin (%) | |
| Face Value (₹) | |
| ROCE(%) |
About Nippon India Nifty Pharma ETF
| NSE Symbol | PHARMABEES |
|---|
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|
No Records Found
Latest News
Suraj Products informs about disclosure
Lee & Nee Softwares (Exports) informs about newspaper publication
Neo Infracon informs about disclosure
PVP Ventures informs about filing of corrigendum to key information document
Pursuant to the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the SEBI (Issue and Listing of Non-Convertible Securities) Regulations, 2021, PVP Ventures has informed that it enclosed a Corrigendum to the Key Information Document dated 28th March 2025 issued in connection with the Company’s listed Non-Convertible Debentures. The Corrigendum, incorporates the repayment schedule forming part of the terms of the Debentures and provides certain clarifications to the Key Information Document.
The above information is a part of company’s filings submitted to BSE.
Prime Industries re-submits audited financial results
In continuation of earlier submission dated May 29, 2026 regarding Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026, Prime Industries has re-submitted the complete set of Financial Results in response to the query received from the esteemed office. This submission includes the Independent Audit Report as required. The company has enclosed the following documents: (a) The Standalone and Consolidated Audited Financial Results for the quarter and financial year ended March 31, 2026; (b) Auditor’s Report on Standalone and Consolidated Audited Financial Results for the said period; (b) Declaration pursuant to Regulation 33 (3) (d) of the Listing Regulations regarding audit report with unmodified opinion.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Nippon India Nifty Pharma ETF is ₹24.75 as of 2026-06-17.
The market capitalisation of Nippon India Nifty Pharma ETF is ₹ as of .
The 1-year return of Nippon India Nifty Pharma ETF is 0.00% as of 2026-06-17.
The P/E ratio of Nippon India Nifty Pharma ETF is as of .
The 52-week high and low of Nippon India Nifty Pharma ETF are ₹ and ₹, respectively, as of 2026-06-17.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
